RT Journal Article
SR Electronic
T1 Mid-life leukocyte telomere length and dementia risk: a prospective cohort study of 435,046 UK Biobank participants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.30.22277121
DO 10.1101/2022.06.30.22277121
A1 Liu, Rui
A1 Xiang, Meiruo
A1 Pilling, Luke C.
A1 Melzer, David
A1 Wang, Lihong
A1 Manning, Kevin J.
A1 Steffens, David C.
A1 Bowden, Jack
A1 Fortinsky, Richard H.
A1 Kuchel, George A.
A1 Rhee, Taeho G
A1 Diniz, Breno S.
A1 Kuo, Chia-Ling
YR 2022
UL http://medrxiv.org/content/early/2022/07/20/2022.06.30.22277121.abstract
AB Importance Telomere attribution is one of biological aging hallmarks and may be intervened to target multiple aging-related diseases, including Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD).Objective To assess associations of leukocyte telomere length (TL) with AD/ADRD and early markers of AD/ADRD, including cognitive performance and brain magnetic resonance imaging (MRI) phenotypes.Design, Setting, and Participants Data from European-ancestry participants in the UK Biobank (n=435,046) were used to evaluate whether mid-life leukocyte TL is associated with incident AD/ADRD over a mean follow-up of 12.2 years. In a subsample without AD/ADRD and with brain imaging data (n=43,390), we associated TL with brain MRI phenotypes related to AD or vascular dementia pathology.Exposures Relative mean leukocyte TL at baseline was measured in T/S ratio, using a multiplex quantitative polymerase chain reaction technique by comparing the amount of the telomere amplification product (T) to that of a single-copy gene (S).Main Outcomes and Measures AD/ADRD was confirmed by mapping multi-source data to 3-charcter ICD codes (G30; F00; F01; F03; G31), excluding other-cause dementias (F02).Results Longer TL was associated with a lower risk of incident AD/ADRD (adjusted HR [aHR] per SD=0.93, 95% CI 0.90 to 0.96, P=3.37×10−7). Longer TL also was associated with better cognitive performance in specific cognitive domains, larger hippocampus volume (adjusted standardized β [aβ] per SD=0.012, 95% CI 0.003 to 0.021, P=0.012), lower total volume of white matter hyperintensities (aβ per SD= -0.015, 95% CI -0.024 to -0.006, P=0.002), and higher fractional anisotropy (FA; aβ per SD=0.018, 95% CI 0.009 to 0.027, P=9.44×10−5) and lower mean diffusivity (MD; aβ per SD=0.045, 95% CI 0.035 to 0.056, P=1.07×10−17) in the fornix.Conclusions and Relevance Longer TL is a protective factor against AD/ADRD, cognitive impairment, and brain structural lesions toward the development of AD/ADRD. A better understanding of underlying mechanisms may help improve diagnosis and management of AD/ADRD in older adults.Question Is leukocyte telomere length (TL) associated with Alzheimer’s disease (AD) and AD related dementias (AD/ADRD) and early markers of AD/ADRD, including cognitive performance and brain magnetic resonance imaging phenotypes?Findings Longer TL was associated with a lower risk of incident AD/ADRD, larger hippocampus volume, lower total volume of white matter hyperintensities, higher fractional anisotropy and lower mean diffusivity in the fornix.Meaning Longer TL in midlife may play a protective role against AD/ADRD, and a better understanding of underlying mechanisms may help improve diagnosis and management of AD/ADRD in older adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Institute of Nursing Research, National Institutes of Health, USA (R21NR018963-01A1S1). K.J.M., D.C.S, R.H.F., G.A.K. and C.L.K. were supported by P30AG067988.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was conducted using the UK Biobank resources under application no. 14631.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.